Fortitude Advisory Group’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
Fortitude Advisory Group's VRTX Position: Q2 2026 in Review
Fortitude Advisory Group opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2026: 517 shares worth $257K. The stake represents 0.1% of the portfolio and ranks #181 among its holdings. This is a return to the name: Fortitude Advisory Group previously reported a position in VRTX as recently as Q1 2022.
Fortitude Advisory Group first reported a position in VRTX in Q4 2021 and has held it in 3 quarters since. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Fortitude Advisory Group held 517 shares of Vertex Pharmaceuticals worth $257K as of Q2 2026.
- Vertex Pharmaceuticals was a new Fortitude Advisory Group position in Q2 2026.
- Vertex Pharmaceuticals made up 0.1% of Fortitude Advisory Group's portfolio in Q2 2026, its #181 holding.
- Fortitude Advisory Group first reported a position in Vertex Pharmaceuticals in Q4 2021 and has held it in 3 quarters since.
- 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Fortitude Advisory Group's 13F filing for Q2 2026, filed 22 Jul 2026.